Clinical Trial Update: Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a neoantigen DNA vaccine in pancreatic cancer patients after surgery and adjuvant chemotherapy; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Cancer, Pancreas Cancer | Phase 1 | Status: TERMINATED | Results posted: 2022-10-04